EMA – Publication of the 6th revision of the Guideline on the clinical evaluation of anticancer medicinal products
The EMA published the Revision 6 of its the Guideline on the clinical evaluation of anticancer medicinal products.
The purpose of this guideline is to provide guidance on all stages of clinical drug development for the treatment of malignancies, including identifying target population with optimised benefit risk in exploratory trials, design of confirmatory trials, choice of endpoints, the impact of adverse drug reactions on the benefit-risk.
More information on the EMA Website.
OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (1 juin 2024). EMA – Publication of the 6th revision of the Guideline on the clinical evaluation of anticancer medicinal products. ELSIBI. Consulté le 18 février 2026 à l’adresse https://doi.org/10.58079/11rn8





